- Advanced search
Receptor serine/threonine kinases (RTSK), EC 18.104.22.168, respond to particular cytokines, the transforming growth factor β (TGFβ) and bone morphogenetic protein (BMP) families, and may be divided into two subfamilies on the basis of structural similarities. Agonist binding initiates formation of a cell-surface complex of type I and type II RSTK, possibly heterotetrameric, where where both subunits express serine/threonine kinase activity. The type I receptor serine/threonine kinases are also known as activin receptors or activin receptor-like kinases, ALKs, for which a systematic nomenclature has been proposed (ALK1-7). The type II protein phosphorylates the kinase domain of the type I partner (sometimes referred to as the signal propagating subunit), causing displacement of the protein partners, such as the FKBP12 FK506-binding protein FKBP1A (P62942) and allowing the binding and phosphorylation of particular members of the Smad family. These migrate to the nucleus and act as complexes to regulate gene transcription. Type III receptors, sometimes called co-receptors or accessory proteins, regulate the signalling of the receptor complex, in either enhancing (for example, presenting the ligand to the receptor) or inhibitory manners. TGFβ family ligand signalling may be inhibited by endogenous proteins, such as follistatin (FST, P19883), which binds and neutralizes activins to prevent activation of the target receptors.
Endogenous agonists, approximately 30 in man, are often described as paracrine messengers acting close to the source of production. They are characterized by six conserved cysteine residues and are divided into two subfamilies on the basis of sequence comparison and signalling pathways activated, the TGFβ/activin/nodal subfamily and the BMP/GDF (growth/differentiation factor)/MIS (Müllerian inhibiting substance) subfamily. Ligands active at RSTKs appear to be generated as large precursors which undergo complex maturation processes . Some are known to form disulphide-linked homo- and/or heterodimeric complexes. Thus, inhibins are α subunits linked to a variety of β chains, while activins are combinations of β subunits.
* Key recommended reading is highlighted with an asterisk
Bragdon B, Moseychuk O, Saldanha S, King D, Julian J, Nohe A. (2011) Bone morphogenetic proteins: a critical review. Cell. Signal., 23 (4): 609-20. [PMID:20959140]
Clarke DC, Liu X. (2008) Decoding the quantitative nature of TGF-beta/Smad signaling. Trends Cell Biol., 18 (9): 430-42. [PMID:18706811]
* Ehrlich M, Horbelt D, Marom B, Knaus P, Henis YI. (2011) Homomeric and heteromeric complexes among TGF-β and BMP receptors and their roles in signaling. Cell. Signal., 23 (9): 1424-32. [PMID:21515362]
Gatza CE, Oh SY, Blobe GC. (2010) Roles for the type III TGF-beta receptor in human cancer. Cell. Signal., 22 (8): 1163-74. [PMID:20153821]
* Hinck AP. (2012) Structural studies of the TGF-βs and their receptors - insights into evolution of the TGF-β superfamily. FEBS Lett., 586 (14): 1860-70. [PMID:22651914]
Kang JS, Liu C, Derynck R. (2009) New regulatory mechanisms of TGF-beta receptor function. Trends Cell Biol., 19 (8): 385-94. [PMID:19648010]
Kardassis D, Murphy C, Fotsis T, Moustakas A, Stournaras C. (2009) Control of transforming growth factor beta signal transduction by small GTPases. FEBS J., 276 (11): 2947-65. [PMID:19490100]
Li MO, Flavell RA. (2008) TGF-beta: a master of all T cell trades. Cell, 134 (3): 392-404. [PMID:18692464]
* Massagué J. (2012) TGFβ signalling in context. Nat. Rev. Mol. Cell Biol., 13 (10): 616-30. [PMID:22992590]
Miyazono K, Kamiya Y, Morikawa M. (2010) Bone morphogenetic protein receptors and signal transduction. J. Biochem., 147 (1): 35-51. [PMID:19762341]
* Moustakas A, Heldin CH. (2009) The regulation of TGFbeta signal transduction. Development, 136 (22): 3699-714. [PMID:19855013]
Pardali E, Goumans MJ, ten Dijke P. (2010) Signaling by members of the TGF-beta family in vascular morphogenesis and disease. Trends Cell Biol., 20 (9): 556-67. [PMID:20656490]
* Rider CC, Mulloy B. (2010) Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists. Biochem. J., 429 (1): 1-12. [PMID:20545624]
* Santibañez JF, Quintanilla M, Bernabeu C. (2011) TGF-β/TGF-β receptor system and its role in physiological and pathological conditions. Clin. Sci., 121 (6): 233-51. [PMID:21615335]
Shi Y, Massagué J. (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell, 113 (6): 685-700. [PMID:12809600]
Sprague AH, Khalil RA. (2009) Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem. Pharmacol., 78 (6): 539-52. [PMID:19413999]
Xia Y, Schneyer AL. (2009) The biology of activin: recent advances in structure, regulation and function. J. Endocrinol., 202 (1): 1-12. [PMID:19273500]
Xiao YT, Xiang LX, Shao JZ. (2007) Bone morphogenetic protein. Biochem. Biophys. Res. Commun., 362 (3): 550-3. [PMID:17719560]
* Xu P, Liu J, Derynck R. (2012) Post-translational regulation of TGF-β receptor and Smad signaling. FEBS Lett., 586 (14): 1871-84. [PMID:22617150]
Yoshimura A, Wakabayashi Y, Mori T. (2010) Cellular and molecular basis for the regulation of inflammation by TGF-beta. J. Biochem., 147 (6): 781-92. [PMID:20410014]
Zeng S, Chen J, Shen H. (2010) Controlling of bone morphogenetic protein signaling. Cell. Signal., 22 (6): 888-93. [PMID:20060893]
1. DaCosta Byfield S, Major C, Laping NJ, Roberts AB. (2004) SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol. Pharmacol., 65 (3): 744-52. [PMID:14978253]
2. Li MO, Flavell RA. (2008) TGF-beta: a master of all T cell trades. Cell, 134 (3): 392-404. [PMID:18692464]
3. Vogt J, Traynor R, Sapkota GP. (2011) The specificities of small molecule inhibitors of the TGFß and BMP pathways. Cell. Signal., 23 (11): 1831-42. [PMID:21740966]
4. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N et al.. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest., 108 (8): 1167-74. [PMID:11602624]
Database page citation:
Receptor serine/threonine kinase (RSTK) family. Accessed on 27/03/2017. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=303.
Concise Guide to PHARMACOLOGY citation:
Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Southan C, Davies JA and CGTP Collaborators (2015) The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors. Br J Pharmacol. 172: 5979-6023.